

Neural Stem Cells and

by **Charles Scerri** BPharm (Hons) MPhil PhD (Dundee) MIBiol EurProBiol
Department of Pathology, Faculty of Medicine and Surgery, University of Malta

Aging is usually associated with progressive loss of central nervous system functions particularly in the presence of neurodegenerative disorders such as Parkinson's and Alzheimer's diseases. In the last few years, cell replacement strategies have been put forward in order to repair the brain and replace the lost brain tissue due to disease. However, successful application of such therapies require the full understanding and knowledge of the complex relationships involved between neural stem cells, normal aging and the neuropathology involved.

The human brain has the ability to retain normal function for a considerable number of years. However, the emergence of neurodegenerative disorders associated with old age is becoming increasingly common. For example, the prevalence of Alzheimer's disease increases from 2-3% in individuals having 65 years of age to around 40-45% in those over the age of 85 years.¹ The sharp rise in life expectancy in many developed and developing countries not only leads to the explosive growth in the numbers and proportion of older persons but also in the incidence of neurodegenerative disorders associated with age. It is therefore not surprising that a lot of attention has been devoted to the recent advances in stem cell therapies which can offer the potential of replacing brain cells in the aging and diseased brain.

The Aging Brain

Similarly to other organs, the brain undergoes a progressive decline in function with increasing age.² In the central nervous system, normal aging (in the absence of any neuropathology) is associated with altered structural changes. The number of brain cells decreases in many areas of the brain and post-mortem studies indicate a reduction of around 5% in brain volume per decade after the age of 40 years.³ There is also an increase in the size of the ventricles, shrinkage of several brain areas such as the frontal cortex and the striatum, and loss in the number of synapses, especially in the prefrontal cortex. On a cellular level, aging of the central nervous system is accompanied by a number of changes that impair cellular function. Oxidative stress increases, damage to both DNA and protein accumulates, cellular metabolism is impaired and lipid and protein by-products accumulate in the brain.⁴ Mitochondrial function also declines, with an associated increase in mitochondrial DNA oxidation and impairment of DNA repair.⁵ A

significant number of signal transduction pathways are also altered, leading to reduced efficiency in neurotransmitter release. Although these changes per se do not cause neurodegeneration, they may predispose the brain to pathologies such as Alzheimer's and Parkinson's diseases.

One of the most remarkable changes that occur in the brain is the alteration in cognitive performance. Compared to young individuals, older adults show different patterns of brain activation when performing cognitive tasks. Most notably, there is age-related impairment in short-term memory and cellular repair capacity, with the latter mostly evident in the presence of neurodegenerative disease.

Age-related Neuropathology

Three of the most prevalent age-related neurodegenerative disorders are Alzheimer's disease, Parkinson's disease and stroke. All three share a common feature: specific populations of brain cells are affected. In Alzheimer's disease, a disorder which mainly affects memory and cognitive function, the brain regions mostly affected are the hippocampus and the cerebral cortex. In Parkinson's disease, a disorder associated with loss of motor function, there is selective loss of dopamine-producing cells in the substantia nigra. In stroke, characterised by blockage or rupture of a blood vessel, there is selective loss of brain cells in the area supplied by the damaged blood vessel. Traditional therapies for each of these diseases have focused on pharmacological approaches. Because in Alzheimer's disease there is loss of cholinergic function, pharmacological agents that have been developed sought to enhance cholinergic transmission via the inactivation of enzymes that break down acetylcholine.⁶ In Parkinson's disease, therapeutic agents aim to enhance dopaminergic transmission by increasing the levels of its precursor,

L-DOPA, or by blocking enzymes responsible for its breakdown or else by direct stimulation of dopamine receptors.⁷ In stroke, treatment is usually directed towards minimising the secondary damage that follows injury.

Neural Stem Cells

Recent studies have shown that certain areas of the brain are capable of producing new cells, a process known as neurogenesis. During the course of neural development, there is a progressive restriction in the differentiation capacities of the cell. Therefore, embryonic stem cells have pluripotent characteristics (ability to develop in almost all kinds of cells) whereas tissue stem cells have multipotent characteristics and only differentiate into a subset of cells related to the tissue in which they are present. Neural stem cells can only give rise to three major types of cells in the central nervous system: neurons, astroglia and oligodendrocytes. Under normal conditions, there are several possible outcomes for a neural stem cell. Stem cells may remain quiescent and not undergo division, or may undergo apoptosis and cease to exist. Alternatively, stem cells may proliferate to produce new stem cells or else differentiate into a mature brain cell. This outcome is regulated by a variety of factors such as growth factors, receptor expression and neurotrophic factors.

Role of Neural Stem Cells in the Aging Brain

In the adult mammalian brain, neural stem cells are located in two major areas of the brain: the olfactory bulb and the hippocampus. Studies show that age-induced stress factors such as an increase in oxidative stress and DNA damage inhibit the formation of neural stem cells. This is most evident during development. For example, prenatal stress inhibits neurogenesis and affects learning and memory in

the Aging Brain - Part I

the adult hippocampus.⁸ Other factors have been found to have a profound effect on neurogenesis including the presence of an enriched environment, exercise, ischemia and antidepressant drug therapy. Neurogenesis also decreases with age even in the absence of any neurodegenerative condition. This is mostly evident in the hippocampus.⁹ Neural stem cells may also have a role in age-related diseases of the brain. Amyloid plaques, which play an important role in the pathology of Alzheimer's disease, not only inhibit the proliferation of neural stem cells but also promote apoptotic cell death. Individuals with early-onset Alzheimer disease (of which a genetic component is the main contributor) exhibit as much as 75% loss of neurons in the olfactory bulb leading to a significant loss of smell.¹⁰ A decrease in the proliferation of neural stem cells in the hippocampus may also contribute to the pathology of Alzheimer's disease and the associated loss of cognitive functions. ☐

References

1. Scerri C. The face of dementia. *BOLD – Journal of the International Institute of Ageing* 2005; 15(3):19-22.
2. Persson J, Nyberg L. Altered brain activity in healthy seniors: what does it mean? *Prog Brain Res* 2006; 157:45-56.
3. Kemper T. Neuroanatomical and neuropathological changes during aging and in dementia. In: Albert M, Knoepfel J, editors. *Clinical Neurology of Aging*. New York: Oxford University Press; 1994. 3-67.
4. Humphries KM, Szweda PA, Szweda LI. Aging: a shift from redox regulation to oxidative damage. *Free Radic Res* 2006; 40:1239-43.
5. Sastre J, Pallardo FV, Vina J. Mitochondrial oxidative stress plays a key role in aging and apoptosis. *IUBMB Life* 2000; 49:427-35.
6. Scerri C. Pharmacotherapeutic approaches in the treatment of Alzheimer's Disease. *J Malta Coll Pharm Pract* 2006; 11:8-10.
7. Bonuccelli U, Del Dotto P. New pharmacologic horizons in the treatment of Parkinson's disease. *Neurology* 2006; 67(7 Suppl 2):S30-8.
8. Neep SA, Gomez-Pinilla F, Choi J, Cotman CW. Physical activity increases mRNA for brain derived neurotrophic factor and nerve growth factor in rat brain. *Brain Res* 1996; 726:49-56.
9. Montaron MF, Petry KG, Rodriguez JJ et al. Adrenalectomy increases neurogenesis but not PSA-NCAM expression in aged dentate gyrus. *Eur J Neurosci* 1999; 11:1479-85.
10. Devanand DP, Michaels-Marston KS, Liu X et al. Olfactory deficits in patients with mild cognitive impairment predict Alzheimer's disease at follow-up. *Am J Psychiat* 2000; 157:1399-1405.

Bayer HealthCare
Bayer Schering Pharma

Air.... Avalox.[®]

In respiratory tract infections: **Premium Class!**

**Acute Exacerbating Chronic Bronchitis (AECB),
Acute Bacterial Rhinosinusitis (ABS) and
Community-Acquired Pneumonia (CAP).**
Avalox[®] is a breath of fresh air in therapy.

Fast take off: rapid eradication of bacteria,¹
quick relief of symptoms².

Long distance: better prognosis³,
fewer treatment failure and recurrence rates⁴.

Short flight time: 5-10 days, just one tablet per day.

Safe landing: superior rates of clinical recovery
over the short and long term².

Check in to the Premium Class.



Check in, take off, breathe better.

Avalox[®]
Premium Class

1 Wiedemann B Poster presented at ECCMID 1999; 2 Kreis S R et al. *J Clin Outcomes Manag* (2000); 7: 33-37;
3 Wilson R et al. *Thorax* 2006; 61: 337-42; 4 Keating K et al. *Curr Med Res and Opin* 2006; 22(2): 327-33

Abbreviated Prescribing Information: See local prescribing information for full details. **Avalox[®] film-coated tablet** or infusion solution (polyolefin flexibags or glass bottles) containing 400 mg moxifloxacin. **Indications:** Respiratory Tract Infections. Acute exacerbations of chronic bronchitis, Community-acquired Pneumonia, Acute Sinusitis, Skin and Soft Tissue Infections. Treatment is indicated for adults (18 yr of age). **Dosage:** The recommended daily dose is one tablet or infusion solution (500 mg once daily) for all indications. Infusion rate for the infusion solution: 30 minutes. General recommendation for acute exacerbation of chronic bronchitis: 5 days, community-acquired pneumonia: 10 days, acute sinusitis: 7 days, skin and soft tissue infections: 7 days. Moxifloxacin can be administered orally or intravenously for the entire treatment duration. Alternatively, therapy may be initiated intravenously, followed by oral tablet administration when allowed by the patient's condition. **Contraindications:** Hypersensitivity to moxifloxacin or other ingredients of the infusion solution or other quinolones, children, growing adolescents, pregnancy, nursing mothers. **Precautions:** known or suspected CNS disorders (seizures), severe hepatic impairment, patients with known prolongation of the QT interval, uncorrected hypocalcemia and patients receiving class IA or class III antiarrhythmic agents, concomitant use of QT interval prolonging drugs, proarrhythmic conditions, recommended dose and infusion rate of 60 minutes should not be exceeded as this may increase QT prolongation which may lead to an increased risk for ventricular arrhythmias including torsades de pointes, orthostatic hypotension, pseudomonas colitis, extensive exposure to either UV irradiation or sunlight, in some instances hypersensitivity, allergic reactions and arthropathy reactions will like threatening shock after first administration. **Interactions:** Antacids, anti-retroviral drugs and other preparations containing magnesium, aluminum, sucralose and other agents containing iron or zinc should be administered at least 4 hours before or 2 hours after ingestion of an oral moxifloxacin dose. Carbic medication reduces systemic exposure after intravenous drug administration approx. 20% and after oral drug administration more than 80%. **Side effects:** $\geq 1\%$ < 10% abdominal pain, headache, injection site reaction, QT prolongation in patients with concomitant hypocalcemia, dizziness, diarrhea, vomiting, dyspepsia, abnormal liver function test, taste perversion, dizziness < 0.1% < 1% asthenia, myalgia, pain, malaise, chest pain, tachycardia, hypotension, palpitation, QT prolongation, phlebitis (at infusion site), dry mouth, nausea and vomiting, tinnitus, constipation, oral moniliasis, sorexenia, stomatitis, gastroenteritis disorder, glossitis, gGT increase, leukopenia, prothrombin decrease, eosinophilia, thrombocytopenia, amylase increased, arthralgia, myalgia, rash, urticaria, myoclonus, somnolence, anxiety, tremor, paresthesia, dyspnea, pain, pruritus, swelling, vagitus, morbilliform, vaginitis < 0.01% < 0.1% pelvic pain, back pain, site test abnormal, allergic reaction, leg pain, hypotension, vasodilation, peripheral edema, gastric, tongue discoloration, dysphagia, parosmia, diarrhea (Clostridium difficile), thrombocytopenia decrease, prothrombin increase, thrombopenia, asthenia, hyperparathyroidism, hypophosphatemia, L-DH increase in connection with abnormal liver function, encephalopathy, disorder, hallucinations, depersonalization, hypotonia, rhabdomyolysis, agitation, amnesia, aphasia, emotional lability, sleep disorders, speech disorders, thinking abnormal, hyposthesia, abnormal dreams, convulsion, depression, asthma, rash (maculopapular, purpuric, pustular), urticaria, brachy, lacrimation, vision, taste loss, parosmia (including smell perversion, decreased smell and loss of smell), arthralgia, kidney function abnormal < 0.01% anaphylactic reaction, shock (anaphylactic, possibly life threatening), pseudomonas colitis, tendon rupture. Common changes in laboratory parameters without regard to drug relationship: increased and decreased hemoglobin, increased WBC, increased and decreased FBC, decreased blood glucose, decreased hemoglobin, increased alkaline phosphatase, increased SGOT/AST, increased SGPT/ALT, increased bilirubin, increased urea, increased creatinine, increased BUN. Ability to drive or operate machinery may be impaired. **Since dosage forms, indications or other information may vary from country to country, please consult your local prescribing information. For further information contact the local Bayer Schering Pharma representative.**